21. Nat Genet. 2018 Jun 11. doi: 10.1038/s41588-018-0142-8. [Epub ahead of print]Association analyses of more than 140,000 men identify 63 new prostate cancersusceptibility loci.Schumacher FR(1)(2), Al Olama AA(3)(4), Berndt SI(5), Benlloch S(6)(7), AhmedM(7), Saunders EJ(7), Dadaev T(7), Leongamornlert D(7), Anokian E(7),Cieza-Borrella C(7), Goh C(7), Brook MN(7), Sheng X(8), Fachal L(9)(10), DennisJ(6), Tyrer J(6), Muir K(11)(12), Lophatananon A(11)(12), Stevens VL(13), GapsturSM(13), Carter BD(13), Tangen CM(14), Goodman PJ(14), Thompson IM Jr(15), BatraJ(16)(17), Chambers S(18)(19), Moya L(16)(17), Clements J(16)(17), HorvathL(20)(21), Tilley W(22), Risbridger GP(23)(24), Gronberg H(25), Aly M(26)(27),Nordström T(25)(28), Pharoah P(6)(10), Pashayan N(10)(29), Schleutker J(30)(31), Tammela TLJ(32), Sipeky C(30), Auvinen A(33), Albanes D(5), Weinstein S(5), Wolk A(34)(35), Håkansson N(34), West CML(36), Dunning AM(10), Burnet N(37), MucciLA(38), Giovannucci E(38), Andriole GL(39), Cussenot O(40)(41), Cancel-TassinG(40)(41), Koutros S(5), Beane Freeman LE(5), Sorensen KD(42)(43), OrntoftTF(42)(43), Borre M(43)(44), Maehle L(45), Grindedal EM(45), Neal DE(46)(47)(48),Donovan JL(49), Hamdy FC(48), Martin RM(49), Travis RC(50), Key TJ(50), Hamilton RJ(51), Fleshner NE(51), Finelli A(52), Ingles SA(8), Stern MC(8), RosensteinBS(53)(54), Kerns SL(55), Ostrer H(56), Lu YJ(57), Zhang HW(58), Feng N(59), Mao X(57), Guo X(60), Wang G(61), Sun Z(62), Giles GG(63)(64), Southey MC(65),MacInnis RJ(63)(64), FitzGerald LM(63)(66), Kibel AS(67), Drake BF(39), VegaA(9), Gómez-Caamaño A(68), Szulkin R(69)(70), Eklund M(25), KogevinasM(71)(72)(73)(74), Llorca J(72)(75), Castaño-Vinyals G(71)(72)(73)(74), PenneyKL(76), Stampfer M(76), Park JY(77), Sellers TA(77), Lin HY(78), StanfordJL(79)(80), Cybulski C(81), Wokolorczyk D(81), Lubinski J(81), Ostrander EA(82), Geybels MS(79), Nordestgaard BG(83)(84), Nielsen SF(83)(84), Weischer M(84),Bisbjerg R(85), Røder MA(86), Iversen P(86), Brenner H(87)(88)(89), Cuk K(87),Holleczek B(90), Maier C(91), Luedeke M(91), Schnoeller T(92), Kim J(93),Logothetis CJ(93), John EM(94)(95), Teixeira MR(96)(97), Paulo P(96), CardosoM(96), Neuhausen SL(98), Steele L(98), Ding YC(98), De Ruyck K(99), De MeerleerG(99), Ost P(100), Razack A(101), Lim J(101), Teo SH(102), Lin DW(79)(103),Newcomb LF(79)(103), Lessel D(104), Gamulin M(105), Kulis T(106), Kaneva R(107), Usmani N(108)(109), Singhal S(108)(109), Slavov C(110), Mitev V(107), Parliament M(108)(109), Claessens F(111), Joniau S(112), Van den Broeck T(111)(112), Larkin S(113), Townsend PA(114), Aukim-Hastie C(115), Dominguez MG(116)(117), CastelaoJE(118), Martinez ME(119), Roobol MJ(120), Jenster G(120), van Schaik RHN(121),Menegaux F(122), Truong T(122), Koudou YA(122); Profile Study, Xu J(123), KhawKT(124), Cannon-Albright L(125)(126), Pandha H(115), Michael A(115), ThibodeauSN(127), McDonnell SK(128), Schaid DJ(128), Lindstrom S(80), Turman C(129), MaJ(76), Hunter DJ(129), Riboli E(130), Siddiq A(131), Canzian F(132), KolonelLN(133), Le Marchand L(133), Hoover RN(5), Machiela MJ(5), Cui Z(134), KraftP(129); Australian Prostate Cancer BioResource (APCB); IMPACT Study; Canary PASS Investigators; Breast and Prostate Cancer Cohort Consortium (BPC3); PRACTICAL(Prostate Cancer Association Group to Investigate Cancer-Associated Alterationsin the Genome) Consortium; Cancer of the Prostate in Sweden (CAPS); ProstateCancer Genome-wide Association Study of Uncommon Susceptibility Loci (PEGASUS);Genetic Associations and Mechanisms in Oncology (GAME-ON)/Elucidating LociInvolved in Prostate Cancer Susceptibility (ELLIPSE) Consortium, AmosCI(135)(136)(137), Conti DV(8), Easton DF(6)(10), Wiklund F(25), Chanock SJ(5),Henderson BE(8), Kote-Jarai Z(7), Haiman CA(8), Eeles RA(138)(139).Author information: (1)Department of Population and Quantitative Health Sciences, Case WesternReserve University, Cleveland, OH, USA. frs2@case.edu.(2)Seidman Cancer Center, University Hospitals, Cleveland, OH, USA.frs2@case.edu.(3)Department of Public Health and Primary Care, Centre for Cancer GeneticEpidemiology, University of Cambridge, Strangeways Research Laboratory,Cambridge, UK. aa461@medschl.cam.ac.uk.(4)Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK. aa461@medschl.cam.ac.uk.(5)Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA.(6)Department of Public Health and Primary Care, Centre for Cancer GeneticEpidemiology, University of Cambridge, Strangeways Research Laboratory,Cambridge, UK.(7)Institute of Cancer Research, London, UK.(8)Department of Preventive Medicine, Keck School of Medicine, University ofSouthern California/Norris Comprehensive Cancer Center, Los Angeles, CA, USA.(9)Fundación Pública Galega de Medicina Xenómica-SERGAS, Grupo de MedicinaXenómica, CIBERER, IDIS, Santiago de Compostela, Spain.(10)Department of Oncology, Centre for Cancer Genetic Epidemiology, StrangewaysLaboratory, University of Cambridge, Cambridge, UK.(11)Division of Population Health, Health Services Research and Primary Care,University of Manchester, Manchester, UK.(12)Warwick Medical School, University of Warwick, Coventry, UK.(13)Epidemiology Research Program, American Cancer Society, Atlanta, GA, USA.(14)SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA,USA.(15)CHRISTUS Santa Rosa Hospital-Medical Center, San Antonio, TX, USA.(16)Institute of Health and Biomedical Innovation and School of BiomedicalSciences, Queensland University of Technology, Brisbane, Queensland, Australia.(17)Australian Prostate Cancer Research Centre-Qld, Translational ResearchInstitute, Brisbane, Queensland, Australia.(18)Menzies Health Institute of Queensland, Griffith University, Nathan,Queensland, Australia.(19)Cancer Council Queensland, Fortitude Valley, Queensland, Australia.(20)Chris O'Brien Lifehouse (COBLH), Camperdown, New South Wales, Australia.(21)Garvan Institute of Medical Research, Sydney, New South Wales, Australia.(22)Dame Roma Mitchell Cancer Research Centre, University of Adelaide, Adelaide, South Australia, Australia.(23)Monash Biomedicine Discovery Institute Cancer Program, Prostate CancerResearch Program, Department of Anatomy and Developmental Biology, MonashUniversity, Victoria, Australia.(24)Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne,Australia.(25)Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.(26)Department of Urology, Karolinska University Hospital, Stockholm, Sweden.(27)Department of Molecular Medicine and Surgery, Karolinska Institutet,Stockholm, Sweden.(28)Department of Clinical Sciences at Danderyds Hospital, Karolinska Institutet,Stockholm, Sweden.(29)Department of Applied Health Research, University College London, London, UK.(30)Institute of Biomedicine, University of Turku, Turku, Finland.(31)Tyks Microbiology and Genetics, Department of Medical Genetics, TurkuUniversity Hospital, Turku, Finland.(32)Department of Urology, Tampere University Hospital and Faculty of Medicineand Life Sciences, University of Tampere, Tampere, Finland.(33)Department of Epidemiology, School of Health Sciences, University of Tampere,Tampere, Finland.(34)Division of Nutritional Epidemiology, Institute of Environmental Medicine,Karolinska Institutet, Stockholm, Sweden.(35)Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.(36)Division of Cancer Sciences, Manchester Cancer Research Centre, ManchesterAcademic Health Science Centre and Christie NHS Foundation Trust, University ofManchester, Manchester, UK.(37)Department of Oncology, Oncology Centre, Cambridge University Hospitals NHSFoundation Trust, University of Cambridge, Cambridge, UK.(38)Department of Epidemiology, Harvard T.H. Chan School of Public Health,Boston, MA, USA.(39)Washington University School of Medicine, St. Louis, MO, USA.(40)UPMC Sorbonne Universités, GRC no. 5 ONCOTYPE-URO, Tenon Hospital, Paris,France.(41)CeRePP, Tenon Hospital, Paris, France.(42)Department of Molecular Medicine, Aarhus University Hospital, Aarhus,Denmark.(43)Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.(44)Department of Urology, Aarhus University Hospital, Aarhus, Denmark.(45)Department of Medical Genetics, Oslo University Hospital, Oslo, Norway.(46)Department of Oncology, Addenbrooke's Hospital, University of Cambridge,Cambridge, UK.(47)Cancer Research UK, Cambridge Research Institute, Cambridge, UK.(48)Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK,Faculty of Medical Science, John Radcliffe Hospital, University of Oxford,Oxford, UK.(49)School of Social and Community Medicine, University of Bristol, Bristol, UK.(50)Cancer Epidemiology Unit, Nuffield Department of Population Health,University of Oxford, Oxford, UK.(51)Department of Surgical Oncology, Princess Margaret Cancer Centre, Toronto,Ontario, Canada.(52)Division of Urology, Princess Margaret Cancer Centre, Toronto, Ontario,Canada.(53)Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai,New York, NY, USA.(54)Department of Genetics and Genomic Sciences, Icahn School of Medicine atMount Sinai, New York, NY, USA.(55)Department of Radiation Oncology, University of Rochester Medical Center,Rochester, NY, USA.(56)Department of Pathology, Albert Einstein College of Medicine, Bronx, NY, USA.(57)Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.(58)Second Military Medical University, Shanghai, China.(59)Wuxi Second Hospital, Nanjing Medical University, Wuxi, China.(60)Department of Urology, First Affiliated Hospital, Chongqing MedicalUniversity, Chongqing, China.(61)Department of Urology, Zhongshan Hospital, Fudan University Medical College, Shanghai, China.(62)People's Hospital of Liaoning Province, People's Hospital of China MedicalUniversity, Shenyang, China.(63)Cancer Epidemiology and Intelligence Division, Cancer Council Victoria,Melbourne, Victoria, Australia.(64)Centre for Epidemiology and Biostatistics, Melbourne School of Population andGlobal Health, University of Melbourne, Melbourne, Australia.(65)Precision Medicine, School of Clinical Sciences at Monash Health, MonashUniversity, Clayton, Victoria, Australia.(66)Menzies Institute for Medical Research, University of Tasmania, Hobart,Tasmania, Australia.(67)Division of Urologic Surgery, Brigham and Womens Hospital, Boston, MA, USA.(68)Department of Radiation Oncology, Complexo Hospitalario Universitario deSantiago, SERGAS, Santiago de Compostela, Spain.(69)Division of Family Medicine, Department of Neurobiology, Care Science andSociety, Karolinska, Institutet, Huddinge, Sweden.(70)Scandinavian Development Services, Danderyd, Sweden.(71)ISGlobal, Centre for Research in Environmental Epidemiology (CREAL),Barcelona, Spain.(72)CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.(73)IMIM (Hospital del Mar Research Institute), Barcelona, Spain.(74)Universitat Pompeu Fabra (UPF), Barcelona, Spain.(75)University of Cantabria-IDIVAL, Santander, Spain.(76)Department of Medicine, Channing Division of Network Medicine, Brigham andWomen's Hospital and Harvard Medical School, Boston, MA, USA.(77)Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA.(78)Biostatistics Program, School of Public Health, Louisiana State UniversityHealth Sciences Center, New Orleans, LA, USA.(79)Division of Public Health Sciences, Fred Hutchinson Cancer Research Center,Seattle, WA, USA.(80)Department of Epidemiology, School of Public Health, University ofWashington, Seattle, WA, USA.(81)International Hereditary Cancer Center, Department of Genetics and Pathology,Pomeranian Medical University, Szczecin, Poland.(82)National Human Genome Research Institute, National Institutes of Health,Bethesda, MD, USA.(83)Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen,Denmark.(84)Department of Clinical Biochemistry, Herlev and Gentofte Hospital, CopenhagenUniversity Hospital, Herlev, Denmark.(85)Department of Urology, Herlev and Gentofte Hospital, Copenhagen UniversityHospital, Herlev, Denmark.(86)Copenhagen Prostate Cancer Center, Department of Urology, Rigshospitalet,Copenhagen University Hospital, Copenhagen, Denmark.(87)Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.(88)German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ),Heidelberg, Germany.(89)Division of Preventive Oncology, German Cancer Research Center (DKFZ) andNational Center for Tumor Diseases (NCT), Heidelberg, Germany.(90)Saarland Cancer Registry, Saarbrücken, Germany.(91)Institute for Human Genetics, University Hospital Ulm, Ulm, Germany.(92)Department of Urology, University Hospital Ulm, Ulm, Germany.(93)Department of Genitourinary Medical Oncology, University of Texas-MD AndersonCancer Center, Houston, TX, USA.(94)Cancer Prevention Institute of California, Fremont, CA, USA.(95)Department of Health Research & Policy (Epidemiology) and Stanford CancerInstitute, Stanford University School of Medicine, Stanford, CA, USA.(96)Department of Genetics, Portuguese Oncology Institute of Porto, Porto,Portugal.(97)Biomedical Sciences Institute (ICBAS), University of Porto, Porto, Portugal.(98)Department of Population Sciences, Beckman Research Institute of the City of Hope, Duarte, CA, USA.(99)Faculty of Medicine and Health Sciences, Basic Medical Sciences, GhentUniversity, Ghent, Belgium.(100)Department of Radiotherapy, Ghent University Hospital, Ghent, Belgium.(101)Department of Surgery, Faculty of Medicine, University of Malaya, KualaLumpur, Malaysia.(102)Cancer Research Malaysia (CRM), Outpatient Centre, Subang Jaya MedicalCentre, Selangor, Malaysia.(103)Department of Urology, University of Washington, Seattle, WA, USA.(104)Institute of Human Genetics, University Medical Center Hamburg-Eppendorf,Hamburg, Germany.(105)Department of Oncology, Division of Medical Oncology, Urogenital Unit,University Hospital Centre Zagreb, Zagreb, Croatia.(106)Department of Urology, University Hospital Center Zagreb, University ofZagreb School of Medicine, Zagreb, Croatia.(107)Molecular Medicine Center, Department of Medical Chemistry and Biochemistry,Medical University of Sofia, Sofia, Bulgaria.(108)Department of Oncology, Cross Cancer Institute, University of Alberta,Edmonton, Alberta, Canada.(109)Division of Radiation Oncology, Cross Cancer Institute, Edmonton, Alberta,Canada.(110)Department of Urology and Alexandrovska University Hospital, MedicalUniversity of Sofia, Sofia, Bulgaria.(111)Molecular Endocrinology Laboratory, Department of Cellular and MolecularMedicine, KU Leuven, Leuven, Belgium.(112)Department of Urology, University Hospitals Leuven, Leuven, Belgium.(113)University of Southampton, Southampton General Hospital, Southampton, UK.(114)Division of Cancer Sciences, Manchester Cancer Research Centre, Faculty ofBiology, Medicine and Health, Manchester Academic Health Science Center, NIHRManchester Biomedical Research Centre, Health Innovation Manchester, Universityof Manchester, Manchester, UK.(115)University of Surrey, Guildford, Surrey, UK.(116)Genomic Medicine Group, Galician Foundation of Genomic Medicine, Institutode Investigacion Sanitaria de Santiago de Compostela (IDIS), ComplejoHospitalario Universitario de Santiago, Servicio Galego de Saúde, SERGAS,Santiago de Compostela, Spain.(117)Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.(118)Genetic Oncology Unit, CHUVI Hospital, Instituto de Investigación Biomédica Galicia Sur (IISGS), Complexo Hospitalario Universitario de Vigo, Vigo, Spain.(119)Department of Family Medicine and Public Health, Moores Cancer Center,University of California San Diego, La Jolla, CA, USA.(120)Department of Urology, Erasmus University Medical Center, Rotterdam, TheNetherlands.(121)Department of Clinical Chemistry, Erasmus University Medical Center,Rotterdam, The Netherlands.(122)Cancer & Environment Group, Center for Research in Epidemiology andPopulation Health (CESP), INSERM, University Paris-Sud, University Paris-Saclay, Villejuif, France.(123)Program for Personalized Cancer Care, NorthShore University HealthSystem,Evanston, IL, USA.(124)Clinical Gerontology Unit, University of Cambridge, Cambridge, UK.(125)Division of Genetic Epidemiology, Department of Medicine, University of UtahSchool of Medicine, Salt Lake City, UT, USA.(126)George E. Wahlen Department of Veterans Affairs Medical Center, Salt LakeCity, UT, USA.(127)Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN,USA.(128)Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester,MN, USA.(129)Program in Genetic Epidemiology and Statistical Genetics, Department ofEpidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.(130)Department of Epidemiology and Biostatistics, School of Public Health,Imperial College London, London, UK.(131)Genomics England, Queen Mary University of London, London, UK.(132)Genomic Epidemiology Group, German Cancer Research Center (DKFZ),Heidelberg, Germany.(133)Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, USA.(134)Department of Population and Quantitative Health Sciences, Case WesternReserve University, Cleveland, OH, USA.(135)Department of Biomedical Data Science, Geisel School of Medicine atDartmouth, Lebanon, NH, USA.(136)Department of Molecular and Systems Biology, Geisel School of Medicine atDartmouth, Hanover, NH, USA.(137)Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth,Lebanon, NH, USA.(138)Institute of Cancer Research, London, UK. ros.eeles@icr.ac.uk.(139)Royal Marsden NHS Foundation Trust, London, UK. ros.eeles@icr.ac.uk.Genome-wide association studies (GWAS) and fine-mapping efforts to date haveidentified more than 100 prostate cancer (PrCa)-susceptibility loci. Wemeta-analyzed genotype data from a custom high-density array of 46,939 PrCa casesand 27,910 controls of European ancestry with previously genotyped data of 32,255PrCa cases and 33,202 controls of European ancestry. Our analysis identified 62novel loci associated (P < 5.0 × 10-8) with PrCa and one locus significantlyassociated with early-onset PrCa (≤55 years). Our findings include missensevariants rs1800057 (odds ratio (OR) = 1.16; P = 8.2 × 10-9; G>C, p.Pro1054Arg) inATM and rs2066827 (OR = 1.06; P = 2.3 × 10-9; T>G, p.Val109Gly) in CDKN1B. Thecombination of all loci captured 28.4% of the PrCa familial relative risk, and a polygenic risk score conferred an elevated PrCa risk for men in the ninetieth to ninety-ninth percentiles (relative risk = 2.69; 95% confidence interval (CI):2.55-2.82) and first percentile (relative risk = 5.71; 95% CI: 5.04-6.48) riskstratum compared with the population average. These findings improve riskprediction, enhance fine-mapping, and provide insight into the underlying biologyof PrCa 1 .DOI: 10.1038/s41588-018-0142-8 PMID: 29892016 